Did the FDA find a link between Wegovy and suicidal thoughts?

No, the FDA's review of 91 trials found no evidence linking GLP-1 drugs like Wegovy to an increased risk of suicidal thoughts or behavior.

Which weight-loss drugs are affected by the FDA's warning removal?

The FDA requested label warning removals for GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy, Saxenda, and Eli Lilly's Zepbound.

What is the purpose of GLP-1 drugs according to the FDA?

GLP-1 receptor agonists were initially developed for type 2 diabetes and work by mimicking a gut hormone to suppress appetite.

Home / Health / FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link

FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link

13 Jan

•

Summary

FDA removes warnings about suicidal thoughts for GLP-1 drugs.
Wegovy, Zepbound, and Saxenda are among affected medications.
Review covered over 107,000 patients in 91 clinical trials.

FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link

The U.S. health regulator has directed drugmakers to remove warnings about potential suicidal thoughts from widely used GLP-1 weight-loss drugs. This guidance impacts medications such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, as well as Novo's Saxenda.

The U.S. Food and Drug Administration's request stems from a comprehensive review of clinical trial data. This analysis, involving 91 trials with over 107,000 participants, found no evidence linking GLP-1 receptor agonists to an increased risk of suicidal thoughts or behavior.

Originally developed for type 2 diabetes, GLP-1 drugs mimic a gut hormone to suppress appetite. The FDA's latest conclusion reinforces an earlier preliminary review, asserting that these drugs do not pose a greater psychiatric risk compared to placebos.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.